{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Warfarin+oral+tablets&page=2", "query": { "intervention": "Warfarin oral tablets", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Warfarin+oral+tablets&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Warfarin+oral+tablets&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T02:42:23.175Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03395639", "title": "Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiac Disease" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 168, "start_date": "2018-05-15", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03395639" }, { "nct_id": "NCT00643201", "title": "Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" }, { "name": "Placebo for apixaban", "type": "DRUG" }, { "name": "Placebo for enoxaparin", "type": "DRUG" }, { "name": "Placebo for warfarin", "type": "DRUG" }, { "name": "apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5614, "start_date": "2008-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00643201" }, { "nct_id": "NCT03556592", "title": "Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-13", "completion_date": "2020-06-20", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556592" }, { "nct_id": "NCT02072434", "title": "Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2199, "start_date": "2014-03-25", "completion_date": "2016-02-03", "has_results": true, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072434" }, { "nct_id": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Urothelial Carcinoma (UC)", "Solid Tumor", "Hepatocellular Carcinoma (HCC)", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Non-Clear Cell Renal Cell Carcinoma (nccRCC)", "Drug-Drug Interaction (DDI)" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "DDI Probe Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1394, "start_date": "2021-12-14", "completion_date": "2030-06-28", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176483" }, { "nct_id": "NCT00403767", "title": "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Embolism" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Matching placebo for Rivaroxaban arm (Warfarin placebo)", "type": "DRUG" }, { "name": "Matching placebo for Warfarin arm (Rivaroxaban placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14269, "start_date": "2006-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 295, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403767" }, { "nct_id": "NCT01006876", "title": "Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thromboembolism" ], "interventions": [ { "name": "Coumadin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Texas Cardiac Arrhythmia Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1584, "start_date": "2010-01", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2015-05-20", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01006876" }, { "nct_id": "NCT02798471", "title": "Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)", "Pulmonary Embolism", "Deep Vein Thrombosis (DVT)" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 290, "start_date": "2017-03-27", "completion_date": "2022-05-24", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 22, "location_summary": "Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798471" }, { "nct_id": "NCT00401583", "title": "A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "GW786034 (pazopanib)", "type": "DRUG" }, { "name": "Probe drugs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 24, "start_date": "2006-07-28", "completion_date": "2008-02-20", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00401583" }, { "nct_id": "NCT06215430", "title": "A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Caffeine Tablet", "type": "DRUG" }, { "name": "Omeprazole capsule", "type": "DRUG" }, { "name": "Warfarin tablet", "type": "DRUG" }, { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2021-01-11", "completion_date": "2021-04-15", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-09T02:42:23.175Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06215430" } ] }